Prudential Financial Inc Xencor Inc Transaction History

Prudential Financial Inc

  • $70 Billion
  • Q3 2024

A detailed history of Prudential Financial Inc transactions in Xencor Inc stock. As of the latest transaction made, Prudential Financial Inc holds 63,905 shares of XNCR stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63,905
Previous 65,905 3.03%
Holding current value
$1.5 Million
Previous $1.25 Million 3.05%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024
SELL
$15.7 - $21.65 $31,400 - $43,300
-2,000 Reduced 3.03%
63,905 $1.29 Million
Q2 2024

Aug 13, 2024
SELL
$18.21 - $24.5 $50,805 - $68,355
-2,790 Reduced 4.06%
65,905 $1.25 Million
Q1 2024

May 14, 2024
SELL
$18.65 - $26.52 $23,499 - $33,415
-1,260 Reduced 1.8%
68,695 $1.52 Million
Q4 2023

Feb 13, 2024
SELL
$16.53 - $21.42 $10,546 - $13,665
-638 Reduced 0.9%
69,955 $1.49 Million
Q3 2023

Nov 13, 2023
SELL
$20.08 - $25.39 $71,986 - $91,023
-3,585 Reduced 4.83%
70,593 $1.42 Million
Q2 2023

Aug 11, 2023
BUY
$24.77 - $29.9 $397,682 - $480,044
16,055 Added 27.62%
74,178 $1.85 Million
Q1 2023

May 12, 2023
SELL
$25.95 - $36.95 $50,472 - $71,867
-1,945 Reduced 3.24%
58,123 $1.62 Million
Q4 2022

Feb 14, 2023
SELL
$24.79 - $30.86 $7,313 - $9,103
-295 Reduced 0.49%
60,068 $0
Q3 2022

Nov 04, 2022
SELL
$24.62 - $32.44 $9,355 - $12,327
-380 Reduced 0.63%
60,363 $1.57 Million
Q2 2022

Aug 15, 2022
SELL
$19.74 - $29.01 $1.43 Million - $2.1 Million
-72,250 Reduced 54.33%
60,743 $1.66 Million
Q1 2022

May 13, 2022
BUY
$26.68 - $41.63 $1.9 Million - $2.96 Million
71,080 Added 114.81%
132,993 $3.55 Million
Q4 2021

Feb 14, 2022
SELL
$33.67 - $43.44 $40,909 - $52,779
-1,215 Reduced 1.92%
61,913 $2.48 Million
Q3 2021

Nov 15, 2021
SELL
$30.65 - $35.68 $27,339 - $31,826
-892 Reduced 1.39%
63,128 $2.06 Million
Q2 2021

Aug 16, 2021
SELL
$34.33 - $44.68 $106,869 - $139,088
-3,113 Reduced 4.64%
64,020 $2.21 Million
Q1 2021

May 12, 2021
SELL
$40.81 - $53.88 $1.11 Million - $1.46 Million
-27,188 Reduced 28.82%
67,133 $2.89 Million
Q4 2020

Feb 16, 2021
SELL
$36.63 - $47.63 $5.36 Million - $6.97 Million
-146,250 Reduced 60.79%
94,321 $4.12 Million
Q3 2020

Nov 16, 2020
BUY
$30.09 - $43.02 $1.35 Million - $1.93 Million
44,956 Added 22.98%
240,571 $9.33 Million
Q2 2020

Aug 12, 2020
BUY
$27.76 - $33.42 $3.25 Million - $3.92 Million
117,169 Added 149.36%
195,615 $6.34 Million
Q1 2020

May 12, 2020
SELL
$20.69 - $37.79 $40,759 - $74,446
-1,970 Reduced 2.45%
78,446 $2.34 Million
Q4 2019

Feb 11, 2020
BUY
$32.75 - $41.43 $84,855 - $107,345
2,591 Added 3.33%
80,416 $2.77 Million
Q3 2019

Nov 13, 2019
BUY
$33.73 - $46.27 $2.45 Million - $3.37 Million
72,730 Added 1427.48%
77,825 $2.63 Million
Q2 2019

Aug 08, 2019
SELL
$29.6 - $40.93 $1.1 Million - $1.52 Million
-37,131 Reduced 87.93%
5,095 $0
Q1 2019

May 15, 2019
SELL
$27.85 - $38.09 $31,275 - $42,775
-1,123 Reduced 2.59%
42,226 $0
Q4 2018

Feb 07, 2019
SELL
$32.39 - $42.05 $1.63 Million - $2.12 Million
-50,387 Reduced 53.75%
43,349 $1.57 Million
Q3 2018

Nov 07, 2018
SELL
$35.69 - $47.65 $3.98 Million - $5.32 Million
-111,630 Reduced 54.36%
93,736 $0
Q2 2018

Aug 13, 2018
BUY
$28.41 - $42.41 $3.57 Million - $5.32 Million
125,500 Added 157.14%
205,366 $0
Q1 2018

May 04, 2018
BUY
$21.18 - $33.78 $889,348 - $1.42 Million
41,990 Added 110.86%
79,866 $0
Q4 2017

Feb 13, 2018
BUY
$19.29 - $24.83 $53,549 - $68,928
2,776 Added 7.91%
37,876 $830,000
Q3 2017

Nov 02, 2017
BUY
$19.61 - $23.35 $688,311 - $819,585
35,100
35,100 $804,000

Others Institutions Holding XNCR

# of Institutions
216
Shares Held
71.7M
Call Options Held
2.5K
Put Options Held
7.9K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.4B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Prudential Financial Inc Portfolio

Follow Prudential Financial Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prudential Financial Inc, based on Form 13F filings with the SEC.

News

Stay updated on Prudential Financial Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email